NICE (UK): Cemiplimab can be used as an option to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults if: i)… read more.
Eton Pharmaceuticals, Inc announced that the Company’s new formulation of Khindivi (hydrocortisone) oral solution successfully showed bioequivalence to Alkindi Sprinkle (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation,… read more.
Emergency Medicine & Intensive Care
Exposure to extreme heat and cold is associated with an increased risk of emergency department (ED) visits among people living with dementia, according to data presented at the… read more.
The European Medicines Agency (EMA) has unveiled a series of initiatives designed to address low representation of women in clinical trials and gaps in understanding sex-based differences in… read more.
Teleflex Incorporated announced it has received Biologics License Application (BLA) approval for Ezplaz Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). Ezplaz FDP is… read more.
Merck, known as MSD outside of the United States and Canada, announced the FDA has approved Lipfendra (enlicitide) tablets 20 mg as an adjunct to diet and exercise… read more.
Incyte announced that the EC has approved Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical… read more.
AstraZeneca withdrew its application for the use of Imfinzi (durvalumab) in combination with BCG in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), a type of cancer… read more.
Exercise finds improvements in pain and function may fall short of what patients would notice in daily life, but more studies are needed to make firm conclusions, a… read more.
Mild COVID-19 can cause severe and long-lasting eye problems, according to a study from Linköping University, Sweden. The study also explains why it has been difficult for sufferers… read more.
Sanofi withdrew its application for the use of Dupixent (dupilumab) in the treatment of adults with moderate-to-severe bullous pemphigoid, an autoimmune skin disease causing widespread itching and blisters… read more.
Zevra Therapeutics announced that the CHMP has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC),… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
